JP2010500370A5 - - Google Patents

Download PDF

Info

Publication number
JP2010500370A5
JP2010500370A5 JP2009523966A JP2009523966A JP2010500370A5 JP 2010500370 A5 JP2010500370 A5 JP 2010500370A5 JP 2009523966 A JP2009523966 A JP 2009523966A JP 2009523966 A JP2009523966 A JP 2009523966A JP 2010500370 A5 JP2010500370 A5 JP 2010500370A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
huluc63
ebmt
administration induces
remission
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2009523966A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010500370A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2007/075401 external-priority patent/WO2008019376A2/en
Publication of JP2010500370A publication Critical patent/JP2010500370A/ja
Publication of JP2010500370A5 publication Critical patent/JP2010500370A5/ja
Withdrawn legal-status Critical Current

Links

JP2009523966A 2006-08-07 2007-08-07 多発性硬化症を処置するための抗ｃｓ１抗体を用いる組成物および方法 Withdrawn JP2010500370A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US83625006P 2006-08-07 2006-08-07
US85614406P 2006-11-01 2006-11-01
PCT/US2007/075401 WO2008019376A2 (en) 2006-08-07 2007-08-07 Compositions and methods using anti-cs1 antibodies to treat multiple myeloma

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2013178996A Division JP5775125B2 (ja) 2006-08-07 2013-08-30 多発性骨髄腫を処置するための抗ｃｓｉ抗体を用いる組成物および方法

Publications (2)

Publication Number Publication Date
JP2010500370A JP2010500370A (ja) 2010-01-07
JP2010500370A5 true JP2010500370A5 (https=) 2010-09-30

Family

ID=39033619

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2009523966A Withdrawn JP2010500370A (ja) 2006-08-07 2007-08-07 多発性硬化症を処置するための抗ｃｓ１抗体を用いる組成物および方法
JP2013178996A Active JP5775125B2 (ja) 2006-08-07 2013-08-30 多発性骨髄腫を処置するための抗ｃｓｉ抗体を用いる組成物および方法
JP2015074786A Active JP6005205B2 (ja) 2006-08-07 2015-04-01 多発性骨髄腫を処置するための抗ｃｓｉ抗体を用いる組成物および方法
JP2016172453A Pending JP2017025077A (ja) 2006-08-07 2016-09-05 多発性骨髄腫を処置するための抗ｃｓｉ抗体を用いる組成物および方法

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2013178996A Active JP5775125B2 (ja) 2006-08-07 2013-08-30 多発性骨髄腫を処置するための抗ｃｓｉ抗体を用いる組成物および方法
JP2015074786A Active JP6005205B2 (ja) 2006-08-07 2015-04-01 多発性骨髄腫を処置するための抗ｃｓｉ抗体を用いる組成物および方法
JP2016172453A Pending JP2017025077A (ja) 2006-08-07 2016-09-05 多発性骨髄腫を処置するための抗ｃｓｉ抗体を用いる組成物および方法

Country Status (17)

Country Link
US (3) US7842293B2 (https=)
EP (2) EP2068930B1 (https=)
JP (4) JP2010500370A (https=)
AU (1) AU2007281682B2 (https=)
BR (1) BRPI0716475A2 (https=)
CA (1) CA2660102C (https=)
CY (1) CY1113309T1 (https=)
DK (1) DK2068930T3 (https=)
ES (1) ES2391790T3 (https=)
HR (1) HRP20120934T1 (https=)
IL (1) IL196920A (https=)
MX (1) MX2009001440A (https=)
NO (1) NO345083B1 (https=)
NZ (1) NZ574979A (https=)
PL (1) PL2068930T3 (https=)
PT (1) PT2068930E (https=)
WO (1) WO2008019376A2 (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2007281684C1 (en) 2006-08-07 2013-12-19 Abbvie Biotherapeutics Inc. Methods of treating multiple myeloma using combination therapies based on anti-CS1 antibodies
NZ574979A (en) * 2006-08-07 2012-06-29 Abbott Biotherapeutics Corp Compositions and methods using anti-cs1 antibodies to treat multiple myeloma
WO2009149021A2 (en) 2008-06-02 2009-12-10 Dana-Farber Cancer Institute, Inc. Xbp1, cd138, and cs1 peptides
EP2361263A1 (en) 2008-10-31 2011-08-31 Abbott Biotherapeutics Corp. Use of anti-cs1 antibodies for treatment of rare lymphomas
US20140295497A1 (en) 2011-11-30 2014-10-02 Taymar E. Hartman Vectors and host cells comprising a modified sv40 promoter for protein expression
JP6280546B2 (ja) 2012-06-26 2018-02-14 デル マー ファーマシューティカルズ ジアンヒドロガラクチトール、ジアセチルジアンヒドロガラクチトール、ジブロモズルシトール、又はこれらの類似体若しくは誘導体を用いた、遺伝子多型又はａｈｉ１の調節不全若しくは変異を有する患者におけるチロシンキナーゼインヒビター抵抗性悪性腫瘍を処置するための方法
JP6374392B2 (ja) 2012-11-05 2018-08-15 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド Ｘｂｐ１、ｃｄ１３８およびｃｓ１ペプチド、該ペプチドを含有する薬学的組成物、ならびにかかるペプチドおよび組成物を使用する方法
KR20160061911A (ko) 2013-04-08 2016-06-01 데니스 엠. 브라운 최적하 투여된 화학 화합물의 치료 효과
ES2707057T3 (es) 2013-11-06 2019-04-02 Bristol Myers Squibb Co Combinación de anticuerpos anti-KIR y anti-CS1 para tratar el mieloma múltiple
WO2015069703A1 (en) 2013-11-06 2015-05-14 Bristol-Myers Squibb Company Immunotherapeutic dosing regimens and combinations thereof
AU2015339012B2 (en) 2014-10-31 2020-11-05 Abbvie Biotherapeutics Inc. Anti-CS1 antibodies and antibody drug conjugates
EP3227335A1 (en) 2014-12-04 2017-10-11 Bristol-Myers Squibb Company Combination of anti-cs1 and anti-pd1 antibodies to treat cancer (myeloma)
RS62352B1 (sr) 2015-06-29 2021-10-29 Bristol Myers Squibb Co Imunoterapijski režimi doziranja koji obuhvataju pomalidomid i anti-cs1 antitelo za lečenje kancera
US10537585B2 (en) 2017-12-18 2020-01-21 Dexcel Pharma Technologies Ltd. Compositions comprising dexamethasone
US20220390455A1 (en) 2019-11-05 2022-12-08 Bristol-Myers Squibb Company M-protein assays and uses thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL112969A (en) 1994-03-17 2001-05-20 Baxter Int Pharmaceutical compositions for the treatment of cancer comprising allogenic lymphocytes or their combination with a t-cell activator
US6143292A (en) 1995-05-25 2000-11-07 Baxter International Inc. Allogeneic cell therapy for cancer following allogeneic stem cell transplantation
US7709610B2 (en) * 2003-05-08 2010-05-04 Facet Biotech Corporation Therapeutic use of anti-CS1 antibodies
US20050025763A1 (en) * 2003-05-08 2005-02-03 Protein Design Laboratories, Inc. Therapeutic use of anti-CS1 antibodies
NZ574979A (en) * 2006-08-07 2012-06-29 Abbott Biotherapeutics Corp Compositions and methods using anti-cs1 antibodies to treat multiple myeloma
EP2069478A2 (en) 2006-08-07 2009-06-17 PDL BioPharma, Inc. Use of allogeneic effector cells and anti-cs1 antibodies for selective killing of multiple myeloma cells
AU2007281684C1 (en) 2006-08-07 2013-12-19 Abbvie Biotherapeutics Inc. Methods of treating multiple myeloma using combination therapies based on anti-CS1 antibodies

Similar Documents

Publication Publication Date Title
JP2010500370A5 (https=)
JP2014533279A5 (https=)
JP2010500371A5 (https=)
JP2009518441A5 (https=)
ES2754431T3 (es) Combinación de un anticuerpo anti-cd19 y un inhibidor de la tirosina quinasa de Bruton y usos de la misma
JP2014502955A5 (https=)
JP2016501892A5 (https=)
JP2015532292A5 (https=)
JP2020500181A5 (https=)
CN117222663A (zh) 使用结合nkg2d、cd16和肿瘤相关抗原的多特异性结合蛋白治疗癌症的方法
NO20083793L (no) Antistoffer mot amyloid-beta peptid
JP2013520996A5 (https=)
JP2018500014A5 (https=)
JP2012102122A5 (https=)
PE20241623A1 (es) Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y usos de los mismos
UA109633C2 (uk) Антитіло людини проти тканинного фактора
RU2010145177A (ru) Лекарственное средство для лечения рака печени
JP2015522252A5 (https=)
JP2012121878A5 (https=)
JP2017113019A5 (https=)
JP2010531140A5 (https=)
RU2015122228A (ru) Терапевтические антитела к CD47
JP2009539841A5 (https=)
JP2016506388A5 (https=)
TW201024310A (en) Antitumor combinations containing antibodies recognizing specifically CD38 and vincristine